This study is in progress, not accepting new patients
Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
Summary
- Eligibility
- for people ages 1 year and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AlloVir
- ID
- NCT04693637
- Phase
- Phase 2/3 research study
- Study Type
- Interventional
- Participants
- Expecting 35 study participants
- Last Updated